{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T02:19:59Z","timestamp":1795054799979,"version":"4.10.2"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173139"],"award-info":[{"award-number":["82173139"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Glioblastoma multiforme (GBM), the most aggressive brain cancer, is highly resistant to chemotherapy, which profoundly affects patient survival and prognosis. Temozolomide (TMZ), the sole first-line chemotherapeutic agent for GBM, faces substantial challenges in overcoming this resistance. Despite the belief that TMZ is well-absorbed in the small intestine and can effectively cross the blood-brain barrier due to its small molecular size, emerging evidence suggests that its uptake is not merely through passive diffusion across the lipid bilayer but is regulated by Wnt signaling. However, the precise mechanism governing TMZ uptake remains elusive. GLUT3, which is highly expressed in GBM and primarily functions as a glucose transporter, has emerged as a promising therapeutic target. This study demonstrates that GLUT3 upregulation in GBM cells enhances sensitivity to both TMZ and capecitabine (CAPE). Uptake assays revealed that GLUT3 overexpression (OE) or knockdown (KD) significantly influenced the uptake of these chemotherapeutic agents. We further validated the interaction between GLUT3 and TMZ\/CAPE through molecular docking, dynamics simulations, and MST assay. Site-directed mutagenesis identified eight amino acids involved in GLUT3-mediated binding and transport of TMZ and CAPE. A mouse xenograft model confirmed that GLUT3 OE significantly increases TMZ\/CAPE uptake and cytotoxicity, particularly under fasting conditions. Our findings establish GLUT3 as a multifunctional transporter for TMZ, CAPE, and glucose, thereby enhancing GBM chemosensitivity. These results challenge the prevailing notion that GLUT3\u2019s role in tumors is solely related to glucose transport. Our work suggests tailoring chemotherapy based on GLUT3 expression level in GBM patients and reevaluating GLUT inhibitors in combination with chemotherapeutic agents.<\/jats:p>","DOI":"10.1038\/s41420-025-02664-w","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:51:27Z","timestamp":1755186687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["GLUT3 enhances chemosensitivity in glioblastoma by transporting temozolomide and capecitabine"],"prefix":"10.1038","volume":"11","author":[{"given":"Honglin","family":"Diao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qikai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zebin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0774-954X","authenticated-orcid":false,"given":"Wenhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2664_CR1","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.trecan.2023.07.009","volume":"9","author":"S Heuer","year":"2023","unstructured":"Heuer S, Winkler F. Glioblastoma revisited: from neuronal-like invasion to pacemaking. Trends Cancer. 2023;9:887\u201396.","journal-title":"Trends Cancer"},{"key":"2664_CR2","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.7150\/thno.38147","volume":"10","author":"M Zhao","year":"2020","unstructured":"Zhao M, van Straten D, Broekman MLD, Pr\u00e9at V, Schiffelers RM. Nanocarrier-based drug combination therapy for glioblastoma. Theranostics. 2020;10:1355\u201372.","journal-title":"Theranostics"},{"key":"2664_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/pr.117.014944","volume":"70","author":"A Shergalis","year":"2018","unstructured":"Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N. Current challenges and opportunities in treating glioblastoma. Pharm Rev. 2018;70:412\u201345.","journal-title":"Pharm Rev"},{"key":"2664_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"2664_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1634\/theoncologist.5-2-144","volume":"5","author":"SS Agarwala","year":"2000","unstructured":"Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5:144\u201351.","journal-title":"Oncologist"},{"key":"2664_CR6","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1158\/1078-0432.CCR-07-1719","volume":"14","author":"JN Sarkaria","year":"2008","unstructured":"Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900\u20138.","journal-title":"Clin Cancer Res"},{"key":"2664_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3:198\u2013210.","journal-title":"Genes Dis"},{"key":"2664_CR8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2174\/1871527321666220404180944","volume":"22","author":"V Rao","year":"2023","unstructured":"Rao V, Kumar G, Vibhavari RJA, Nandakumar K, Thorat ND, Chamallamudi MR, et al. Temozolomide resistance: a multifarious review on mechanisms beyond O-6-methylguanine-dna methyltransferase. CNS Neurol Disord Drug Targets. 2023;22:817\u201331.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2664_CR9","first-page":"17","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4:17\u201343.","journal-title":"Cancer Drug Resist"},{"key":"2664_CR10","first-page":"513","volume":"19","author":"R Ortiz","year":"2021","unstructured":"Ortiz R, Perazzoli G, Cabeza L, Jim\u00e9nez-Luna C, Luque R, Prados J, et al. Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Curr Neuropharmacol. 2021;19:513\u201337.","journal-title":"Curr Neuropharmacol"},{"key":"2664_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noac288","volume":"25","author":"Y Xie","year":"2023","unstructured":"Xie Y, He L, Zhang Y, Huang H, Yang F, Chao M, et al. Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma. Neuro Oncol. 2023;25:1073\u201384.","journal-title":"Neuro Oncol"},{"key":"2664_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejpb.2019.01.015","volume":"136","author":"MJ Ramalho","year":"2019","unstructured":"Ramalho MJ, Andrade S, Coelho MAN, Loureiro JA, Pereira MC. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: the relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Eur J Pharm Biopharm. 2019;136:156\u201363.","journal-title":"Eur J Pharm Biopharm"},{"key":"2664_CR13","doi-asserted-by":"crossref","unstructured":"Rubio-Camacho M, Encinar JA, Mart\u00ednez-Tom\u00e9 MJ, Esquembre R, Mateo CR. The interaction of temozolomide with blood components suggests the potential use of human serum albumin as a biomimetic carrier for the drug. Biomolecules. 2020;10:1015.","DOI":"10.3390\/biom10071015"},{"key":"2664_CR14","first-page":"73","volume":"21","author":"Y Zhuang","year":"2018","unstructured":"Zhuang Y, Zhao J, Xu X, Bi L. Downregulation of GLUT3 promotes apoptosis and chemosensitivity of acute myeloid leukemia cells via EGFR signaling. Arch Iran Med. 2018;21:73\u20138.","journal-title":"Arch Iran Med"},{"key":"2664_CR15","doi-asserted-by":"publisher","first-page":"3321409","DOI":"10.1155\/2022\/3321409","volume":"2022","author":"X Li","year":"2022","unstructured":"Li X, Zhao G, Mi X, Xu T, Li X, Liu B. Ajuba overexpression promotes breast cancer chemoresistance and glucose uptake through TAZ-GLUT3\/survivin pathway. Biomed Res Int. 2022;2022:3321409.","journal-title":"Biomed Res Int"},{"key":"2664_CR16","doi-asserted-by":"crossref","unstructured":"Ali R, Alhaj Sulaiman A, Memon B, Pradhan S, Algethami M, Aouida M, et al. Altered regulation of the glucose transporter GLUT3 in PRDX1 null cells caused hypersensitivity to arsenite. Cells. 2023;12:2682.","DOI":"10.3390\/cells12232682"},{"key":"2664_CR17","doi-asserted-by":"publisher","first-page":"217109","DOI":"10.1016\/j.canlet.2024.217109","volume":"598","author":"K Chen","year":"2024","unstructured":"Chen K, Li T, Diao H, Wang Q, Zhou X, Huang Z, et al. SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cells via upregulation of GLUT3 expression. Cancer Lett. 2024;598:217109.","journal-title":"Cancer Lett"},{"key":"2664_CR18","first-page":"2303","volume":"31","author":"W Luo","year":"2011","unstructured":"Luo W, Schork NJ, Marschke KB, Ng SC, Hermann TW, Zhang J, et al. Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer. Anticancer Res. 2011;31:2303\u201311.","journal-title":"Anticancer Res"},{"key":"2664_CR19","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1158\/0008-5472.CAN-06-4495","volume":"67","author":"P Tooker","year":"2007","unstructured":"Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 2007;67:4425\u201333.","journal-title":"Cancer Res"},{"key":"2664_CR20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00424-020-02411-3","volume":"472","author":"GD Holman","year":"2020","unstructured":"Holman GD. Structure, function and regulation of mammalian glucose transporters of the SLC2 family. Pflug Arch. 2020;472:1155\u201375.","journal-title":"Pflug Arch"},{"key":"2664_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.nucmedbio.2010.11.004","volume":"38","author":"M Wuest","year":"2011","unstructured":"Wuest M, Trayner BJ, Grant TN, Jans HS, Mercer JR, Murray D, et al. Radiopharmacological evaluation of 6-deoxy-6-[18\u2009F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer. Nucl Med Biol. 2011;38:461\u201375.","journal-title":"Nucl Med Biol"},{"key":"2664_CR22","doi-asserted-by":"publisher","first-page":"338593","DOI":"10.1016\/j.aca.2021.338593","volume":"1167","author":"S Zhang","year":"2021","unstructured":"Zhang S, Wang X, Zhang R, Cui Y, Zhang H, Song W, et al. A GLUT1 inhibitor-based fluorogenic probe for Warburg effect-targeted drug screening and diagnostic imaging of hyperglycolytic cancers. Anal Chim Acta. 2021;1167:338593.","journal-title":"Anal Chim Acta"},{"key":"2664_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0169-328X(94)90183-X","volume":"27","author":"RJ Boado","year":"1994","unstructured":"Boado RJ, Black KL, Pardridge WM. Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res. 1994;27:51\u20137.","journal-title":"Brain Res Mol Brain Res"},{"key":"2664_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1023\/A:1011115809810","volume":"15","author":"RK Handa","year":"2000","unstructured":"Handa RK, DeJoseph MR, Singh LD, Hawkins RA, Singh SP. Glucose transporters and glucose utilization in rat brain after acute ethanol administration. Metab Brain Dis. 2000;15:211\u201322.","journal-title":"Metab Brain Dis"},{"key":"2664_CR25","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/15384047.2019.1599662","volume":"20","author":"A Arora","year":"2019","unstructured":"Arora A, Somasundaram K. Glioblastoma vs temozolomide: can the red queen race be won?. Cancer Biol Ther. 2019;20:1083\u201390.","journal-title":"Cancer Biol Ther"},{"key":"2664_CR26","doi-asserted-by":"crossref","unstructured":"Lundy DJ, Nguy\u1ec5n H, Hsieh PCH. Emerging nano-carrier strategies for brain tumor drug delivery and considerations for clinical translation. Pharmaceutics. 2021;13:1193.","DOI":"10.3390\/pharmaceutics13081193"},{"key":"2664_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/0022-5193(80)90367-7","volume":"87","author":"SN Mohammad","year":"1980","unstructured":"Mohammad SN, Hopfinger AJ. Chemical reactivity of a methyldiazonium ion with nucleophilic centers of DNA bases. J Theor Biol. 1980;87:401\u20139.","journal-title":"J Theor Biol"},{"key":"2664_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-018-0211-8","volume":"7","author":"D Ghosh","year":"2018","unstructured":"Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate glioblastoma: clinical challenges and advances. Clin Transl Med. 2018;7:33.","journal-title":"Clin Transl Med"},{"key":"2664_CR29","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1089\/1043034041648417","volume":"15","author":"D Chinnasamy","year":"2004","unstructured":"Chinnasamy D, Fairbairn LJ, Neuenfeldt J, Treisman JS, Hanson JP Jr, Margison GP, et al. Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide. Hum Gene Ther. 2004;15:758\u201369.","journal-title":"Hum Gene Ther"},{"key":"2664_CR30","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1179\/1743132813Y.0000000191","volume":"35","author":"PJ Vlachostergios","year":"2013","unstructured":"Vlachostergios PJ, Hatzidaki E, Papandreou CN. MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFkappaB and mutant p53. Neurol Res. 2013;35:879\u201382.","journal-title":"Neurol Res"},{"key":"2664_CR31","doi-asserted-by":"crossref","unstructured":"Wu M, Song D, Li H, Ahmad N, Xu H, Yang X, et al. Resveratrol enhances temozolomide efficacy in glioblastoma cells through downregulated MGMT and negative regulators-related STAT3 inactivation. Int J Mol Sci. 2023;24:9453.","DOI":"10.3390\/ijms24119453"},{"key":"2664_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.245","volume":"5","author":"S Haemmig","year":"2014","unstructured":"Haemmig S, Baumgartner U, Gl\u00fcck A, Zbinden S, Tschan MP, Kappeler A, et al. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis. 2014;5:e1279.","journal-title":"Cell Death Dis"},{"key":"2664_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02895-6","volume":"22","author":"T Yang","year":"2024","unstructured":"Yang T, Zhang N, Liu Y, Yang R, Wei Z, Liu F, et al. Nanoplatelets modified with RVG for targeted delivery of miR-375 and temozolomide to enhance gliomas therapy. J Nanobiotechnol. 2024;22:623.","journal-title":"J Nanobiotechnol"},{"key":"2664_CR34","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1021\/acsomega.0c05399","volume":"6","author":"J Xiong","year":"2021","unstructured":"Xiong J, Guo G, Guo L, Wang Z, Chen Z, Nan Y, et al. Amlexanox enhances temozolomide-induced antitumor effects in human glioblastoma cells by inhibiting IKBKE and the Akt-mTOR signaling pathway. ACS Omega. 2021;6:4289\u201399.","journal-title":"ACS Omega"},{"key":"2664_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01370-6","volume":"28","author":"Y Yan","year":"2023","unstructured":"Yan Y, Liu Y, Liang Q, Xu Z. Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma. Eur J Med Res. 2023;28:373.","journal-title":"Eur J Med Res"},{"key":"2664_CR36","doi-asserted-by":"publisher","first-page":"723","DOI":"10.21873\/anticanres.15530","volume":"42","author":"SD Lustig","year":"2022","unstructured":"Lustig SD, Kodali SK, Longo SL, Kundu S, Viapiano MS. Ko143 reverses MDR in glioblastoma via deactivating p-glycoprotein, sensitizing a resistant phenotype to TMZ treatment. Anticancer Res. 2022;42:723\u201330.","journal-title":"Anticancer Res"},{"key":"2664_CR37","doi-asserted-by":"publisher","first-page":"18175","DOI":"10.1073\/pnas.2006958117","volume":"117","author":"Y Toyoda","year":"2020","unstructured":"Toyoda Y, Takada T, Miyata H, Matsuo H, Kassai H, Nakao K, et al. Identification of GLUT12\/SLC2A12 as a urate transporter that regulates the blood urate level in hyperuricemia model mice. Proc Natl Acad Sci USA. 2020;117:18175\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2664_CR38","doi-asserted-by":"publisher","first-page":"E242","DOI":"10.1152\/ajpendo.90388.2008","volume":"295","author":"IA Simpson","year":"2008","unstructured":"Simpson IA, Dwyer D, Malide D, Moley KH, Travis A, Vannucci SJ. The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endocrinol Metab. 2008;295:E242\u201353.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2664_CR39","first-page":"164","volume":"1835","author":"L Szablewski","year":"2013","unstructured":"Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta. 2013;1835:164\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"2664_CR40","first-page":"670","volume":"21","author":"P Som","year":"1980","unstructured":"Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670\u20135.","journal-title":"J Nucl Med"},{"key":"2664_CR41","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s002800050248","volume":"35","author":"J Pohl","year":"1995","unstructured":"Pohl J, Bertram B, Hilgard P, Nowrousian MR, St\u00fcben J, Wiessler M. D-19575-a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother Pharmacol. 1995;35:364\u201370.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2664_CR42","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1039\/c3sc22205e","volume":"4","author":"EC Calvaresi","year":"2013","unstructured":"Calvaresi EC, Hergenrother PJ. Glucose conjugation for the specific targeting and treatment of cancer. Chem Sci. 2013;4:2319\u201333.","journal-title":"Chem Sci"},{"key":"2664_CR43","doi-asserted-by":"publisher","first-page":"12035","DOI":"10.1002\/anie.201606121","volume":"55","author":"QL He","year":"2016","unstructured":"He QL, Minn I, Wang Q, Xu P, Head SA, Datan E, et al. Targeted delivery and sustained antitumor activity of triptolide through glucose conjugation. Angew Chem Int Ed Engl. 2016;55:12035\u20139.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2664_CR44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0014-2999(96)00796-0","volume":"318","author":"T Halmos","year":"1996","unstructured":"Halmos T, Santarromana M, Antonakis K, Scherman D. Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur J Pharmacol. 1996;318:477\u201384.","journal-title":"Eur J Pharmacol"},{"key":"2664_CR45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.metabol.2015.10.007","volume":"65","author":"CC Barron","year":"2016","unstructured":"Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2016;65:124\u201339.","journal-title":"Metabolism"},{"key":"2664_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07791-y","volume":"21","author":"X Huo","year":"2021","unstructured":"Huo X, Li J, Zhao F, Ren D, Ahmad R, Yuan X, et al. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21:78.","journal-title":"BMC Cancer"},{"key":"2664_CR47","first-page":"456","volume":"5","author":"D Cameron","year":"2007","unstructured":"Cameron D. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. Clin Adv Hematol Oncol. 2007;5:456\u20138.","journal-title":"Clin Adv Hematol Oncol"},{"key":"2664_CR48","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325:50\u20138.","journal-title":"JAMA"},{"key":"2664_CR49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 2023;9:197\u2013205.","journal-title":"JAMA Oncol"},{"key":"2664_CR50","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610\u20139.","journal-title":"J Clin Oncol"},{"key":"2664_CR51","doi-asserted-by":"crossref","unstructured":"Peereboom DM, Alban TJ, Grabowski MM, Alvarado AG, Otvos B, Bayik D, et al. Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight. 2019;4:e130748.","DOI":"10.1172\/jci.insight.130748"},{"key":"2664_CR52","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/jcpt.13166","volume":"45","author":"A Varma","year":"2020","unstructured":"Varma A, Mathaiyan J, Shewade D, Dubashi B, Sunitha K. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India. J Clin Pharm Ther. 2020;45:617\u201327.","journal-title":"J Clin Pharm Ther"},{"key":"2664_CR53","first-page":"4349","volume":"58","author":"JR Mackey","year":"1998","unstructured":"Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998;58:4349\u201357.","journal-title":"Cancer Res"},{"key":"2664_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.blre.2015.08.001","volume":"30","author":"JJ Marin","year":"2016","unstructured":"Marin JJ, Briz O, Rodr\u00edguez-Macias G, D\u00edez-Mart\u00edn JL, Macias RI. Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. Blood Rev. 2016;30:55\u201364.","journal-title":"Blood Rev"},{"key":"2664_CR55","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.bjc.6603559","volume":"96","author":"Y Nakano","year":"2007","unstructured":"Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer. 2007;96:457\u201363.","journal-title":"Br J Cancer"},{"key":"2664_CR56","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/neuonc\/noab015","volume":"23","author":"M Yamamoto","year":"2021","unstructured":"Yamamoto M, Sanomachi T, Suzuki S, Uchida H, Yonezawa H, Higa N, et al. Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma. Neuro Oncol. 2021;23:945\u201354.","journal-title":"Neuro Oncol"},{"key":"2664_CR57","first-page":"5041","volume":"7","author":"T Deng","year":"2014","unstructured":"Deng T, Pan H, Han R, Huang D, Li H, Zhou L, et al. Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer. Int J Clin Exp Med. 2014;7:5041\u20139.","journal-title":"Int J Clin Exp Med"},{"key":"2664_CR58","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1349-7006.2004.tb03257.x","volume":"95","author":"H Achiwa","year":"2004","unstructured":"Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 2004;95:753\u20137.","journal-title":"Cancer Sci"},{"key":"2664_CR59","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/onc.2010.492","volume":"30","author":"A Mart\u00edn-Montalvo","year":"2011","unstructured":"Mart\u00edn-Montalvo A, Villalba JM, Navas P, de Cabo R. NRF2, cancer and calorie restriction. Oncogene. 2011;30:505\u201320.","journal-title":"Oncogene"},{"key":"2664_CR60","doi-asserted-by":"publisher","first-page":"e44603","DOI":"10.1371\/journal.pone.0044603","volume":"7","author":"F Safdie","year":"2012","unstructured":"Safdie F, Brandhorst S, Wei M, Wang W, Lee C, Hwang S, et al. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS ONE. 2012;7:e44603.","journal-title":"PLoS ONE"},{"key":"2664_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-571","volume":"12","author":"Y Shi","year":"2012","unstructured":"Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M, Stahel RA. Starvation-induced activation of ATM\/Chk2\/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer. 2012;12:571.","journal-title":"BMC Cancer"},{"key":"2664_CR62","doi-asserted-by":"publisher","first-page":"18545","DOI":"10.18632\/oncotarget.4186","volume":"6","author":"M D\u2019Aronzo","year":"2015","unstructured":"D\u2019Aronzo M, Vinciguerra M, Mazza T, Panebianco C, Saracino C, Pereira SP, et al. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Oncotarget. 2015;6:18545\u201357.","journal-title":"Oncotarget"},{"key":"2664_CR63","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ccell.2019.03.007","volume":"35","author":"M Elgendy","year":"2019","unstructured":"Elgendy M, Ciro M, Hosseini A, Weiszmann J, Mazzarella L, Ferrari E, et al. Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3beta-MCL-1 axis. Cancer Cell. 2019;35:798\u2013815 e5.","journal-title":"Cancer Cell"},{"key":"2664_CR64","doi-asserted-by":"crossref","unstructured":"Shen S, Iyengar NM. Insulin-lowering diets in metastatic cancer. Nutrients. 2022;14:3542.","DOI":"10.3390\/nu14173542"},{"key":"2664_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.biocel.2015.01.022","volume":"63","author":"S Vidali","year":"2015","unstructured":"Vidali S, Aminzadeh S, Lambert B, Rutherford T, Sperl W, Kofler B, et al. Mitochondria: the ketogenic diet-a metabolism-based therapy. Int J Biochem Cell Biol. 2015;63:55\u20139.","journal-title":"Int J Biochem Cell Biol"},{"key":"2664_CR66","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2174\/0929867324666170116122915","volume":"24","author":"M Vergati","year":"2017","unstructured":"Vergati M, Krasniqi E, Monte GD, Riondino S, Vallone D, Guadagni F, et al. Ketogenic diet and other dietary intervention strategies in the treatment of cancer. Curr Med Chem. 2017;24:1170\u201385.","journal-title":"Curr Med Chem"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02664-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02664-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02664-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:54:29Z","timestamp":1757393669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02664-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2664"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02664-w","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study and the included experimental procedures were approved by the institutional animal care and use Biomedical Ethics Committees of Peking University (Approval No. LA2020220). All animal housing and experiments were conducted in strict accordance with the institutional guidelines for care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"382"}}